. FTSE 100 He exceeded the US markets since the office of President Trump. I am sure that few people had it on bingo cards. Today it may seem obvious, but it was not a few months ago.

And at this point of uncertainty it is crucial to recognize that many postpandemical points of view were wrong. Perhaps everything was “Inflation is temporary ” – It wasn’t.

The main part of the understanding, where the index will be in six months, will reflect the impact of Trump tariffs. Tariffs for Great Britain will be one factor, but it is crucial to remember that FTSE 100 This is a truly global index.

Mining institutions, oil and even banking, which are strongly represented, operate around the world. In fact, I do not believe that none of the FTSE 100 mining companies actively extract in Great Britain – Angloj AmericanThe Woodsmith project is under development.

This is what chatgpt said

First of all, the artificial intelligence platform (AI) suggested that the future of the index is uncertain by nature. However, Chatgpt provided me with two institutional forecasts and pointed to the raise in the index higher in the second half of the year.

• Goldman Sachs’ Improved forecasts: from April 1, 2025, Goldman Sachs corrected its 12-month forecast for the British FTSE 100 to 9 100 points index, compared to previous estimates of 9,000 points.
• AJ Bell’s projections: The AJ Bell investment platform predicted that FTSE 100 can reach 9,000 points by the end of 2025.

However, the platform warned that these forecasts may change based on various factors, including economic development, geopolitical events and changes in the mood of investors. He added that although these analyzes provide a general perspective, they should not be interpreted as final forecasts.

The best contractor

Undecracked by the chatgpt response, I pressed more, asking her to predict the best -working stocks for six months. His answer was Astrasenec (LSE: AZN). Chatgpt noticed that Astrazeneca has “”gain 36%” According to Barclaysdriven by significant progress in the development of anti -cancer drugs and the upcoming results of the examination.

Astrazeneca can actually be an outstanding contractor in FTSE 100 in the next six months. The company has made significant progress in oncology, with recent FDA approval and solid preparation of novel drugs. And the analysts are sanguine, and the consensus recommendation is heavily directed towards buying and elevation assessments. Strong financial results of the company, including an raise in revenues by 21% in 2024, also supports its potential.

However, there is a risk. Astrazeneca must navigate on competitive pressure in oncology and manage regulatory challenges. In addition, achieving ambitious revenues will require flawless implementation and further innovations. What’s more, Trump’s tariffs can be challenges.

Despite these possible speeds, the mighty Astraseneca pipeline and growth prospects make it an attractive choice for investors looking for potential in the pharmaceutical sector. This is something that I really considered buying more.